[1]刘 平,马晓晓,刘宝将,等.82例肝动脉灌注化疗致过敏反应患者的临床特征及护理对策[J].介入放射学杂志,2023,32(12):1242-1245.
 LIU Ping,MA Xiaoxiao,LIU Baojiang,et al.Clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy and its nursing strategy: preliminary results in 82 patients[J].journal interventional radiology,2023,32(12):1242-1245.
点击复制

82例肝动脉灌注化疗致过敏反应患者的临床特征及护理对策()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年12
页码:
1242-1245
栏目:
护理论坛
出版日期:
2024-01-02

文章信息/Info

Title:
Clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy and its nursing strategy: preliminary results in 82 patients
作者:
刘 平 马晓晓 刘宝将 朱 旭 闻利红
Author(s):
LIU Ping MA Xiaoxiao LIU Baojiang ZHU Xu WEN Lihong.
Department of Interventional Therapy, Peking University Cancer Hospital (Beijing Municipal Cancer Prevention and Treatment Institute), Key laboratory of Carcinogenesis and Translational Research Institute of the Ministry of Education, Beijing 100142, China
关键词:
【关键词】 肝动脉灌注化疗 过敏反应 奥沙利铂 护理
文献标志码:
A
摘要:
【摘要】 目的 探讨肝动脉灌注化疗致过敏反应的患者临床特征及护理对策。方法 分析82例患
者过敏反应的临床表现、严重程度分级、发生时间、高危药物、过敏性休克的首发症状等。结果 82例患者中57例(69.5%)为肠癌肝转移,年龄42~82岁,多数为对奥沙利铂过敏(98.8%),Ⅰ度过敏反应常见(80.5%),临床表现以皮肤症状为主,多种症状可同时出现,过敏反应可发生于用药各个时间段,过敏性休克多发生于用药后30 min内,首发症状不典型。结论 奥沙利铂是在肝动脉灌注化疗中导致过敏反应的常见药物,护理人员应熟悉相关药物过敏反应,尤其是过敏性休克的临床症状、特点、护理措施,确保患者治疗安全。

参考文献/References:

[1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2: 1- 9.
[2] 中国抗癌协会肝癌专业委员会.肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20:754- 759.
[3] Liu B, Zhu X, Gao S, et al. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post- transarterial chemoembolization for unresectable hepatocellular carcinoma[J]. J Interv Med, 2019, 2: 91- 96.
[4] Lee MY, Yang MH, Liu JH, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication[J]. Support Care Cancer, 2007, 15: 89- 93.
[5] 刘思源,郭代红,孔祥豪,等. 201299例住院患者过敏反应自动监测研究及相关药物分析[J]. 中国临床药理学杂志, 2021,37:1436- 1440.
[6] 经碧玲,尤国美,余先萍,等. 肝动脉灌注国产奈达铂致过敏反应的观察及护理[J]. 中国实用护理杂志(中旬版), 2010, 10:59- 60.
[7] 邱国钦,罗鹏飞,陈玉强. 动脉用药多西他赛致严重过敏反应一例[J]. 介入放射学杂志, 2012, 21:60- 61.
[8] Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes[J]. Lancet, 1977, 1: 466- 469.
[9] 付巧英,张 红,谷晓月. 83例奥沙利铂过敏反应患者的临床特征分析及护理对策[J]. 当代医学, 2019, 25:92- 95.
[10] Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin[J]. Cancer, 2004, 100: 211- 212.
[11] Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol[J]. Oncologist, 2004, 9: 546- 549.
[12] 张文武. 急诊内科学[M]. 北京:人民卫生出版社, 2001:194- 195.
[13] 朱方勇,陈 颢,花永强,等. 原发性肝癌肝动脉灌注奥沙利铂致过敏反应的临床分析[J]. 肿瘤, 2014, 34:547- 563.
[14] 苏 圆,刘贤铭. 奥沙利铂致过敏反应的文献分析[J]. 中国医院用药评价与分析, 2015, 15:131- 133.
[15] 蔡 强. 奥沙利铂过敏反应临床资料分析[J]. 山东大学学报(医学版), 2011, 49: 149- 152.
[16] 李 敏,钟巧妮,赵 丽,等. 中国患者奥沙利铂过敏反应文献分析[J]. 中国药物警戒, 2020, 17:798- 802.
[17] 薛 静,高 旻,潘 莹,等. 某院奥沙利铂过敏反应临床分析及防治[J]. 中国药物警戒, 2020, 17:361- 365.
[18] 王闫飞,付巧英,陈晓艳,等. 单中心奥沙利铂超敏反应的处理及转归真实世界研究[J]. 中国肿瘤临床, 2020, 47:729- 735.
[19] 廖 莉,文 香,李 芹. 76例药物过敏性休克临床分析[J].重庆医学, 2013, 42:1355- 1356, 1359.

相似文献/References:

[1]邢丽,孙丽霞.肝癌介入治疗术中的护理[J].介入放射学杂志,1997,(02):109.
[2]张彩珍,田巧莲,苏秀琴,等.介入放射治疗中病人的护理[J].介入放射学杂志,1999,(02):54.
[3]王希锐,姜旭,廖顺明,等.泛影葡胺引起急性肾功衰竭致死亡一例[J].介入放射学杂志,1996,(03):129.
[4]何光兰,张丽.经皮冠状动脉支架置入术的护理体会[J].介入放射学杂志,2000,(02):118.
[5]赵东旭,张 磊,姜小庆,等.HAIC是老技术还是新方法——理性看待肝动脉灌注化疗[J].介入放射学杂志,2022,31(01):2.
 ZHAO Dongxu,ZHANG Lei,JIANG Xiaoqing,et al.Is HAIC an obsolete technology or a novel therapeutic method? HAIC should be treated rationally[J].journal interventional radiology,2022,31(12):2.
[6]贾中芝,曹 妍,李绍钦.血管内含镍金属植入物过敏反应研究进展 [J].介入放射学杂志,2022,31(03):307.
 JIA Zhongzhi,CAO Yan,LI Shaoqin..Advances in the study of allergic reactions to nickel-containing metallic endovascular implants[J].journal interventional radiology,2022,31(12):307.
[7]杨 俊,印 于,张 申,等.HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性[J].介入放射学杂志,2023,32(03):229.
 YANG Jun,YIN Yu,ZHANG Shen,et al.The safety and efficacy of sequential hepatic arterial infusion chemotherapy and transarterial embolization for unresectable hepatocellular carcinoma[J].journal interventional radiology,2023,32(12):229.

备注/Memo

备注/Memo:
(收稿日期:2022- 12- 12)
(本文编辑:茹 实)
更新日期/Last Update: 2024-01-02